Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Preclinical studies have suggested that metformin has antitumor effects, likely due to blockage of mTOR pathway through AMPK and decreased insulin levels. A retrospective study showed that metformin combined with everolimus to treat related hyperglycemia offered longer progression-free survival (PFS) in patients (pts) with pancreatic neuroendocrine tumors (NET).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Glasberg J
Authors: Glasberg J, Talans A, Lopez R, Recchimuzzi D, Riechelmann R,
Keywords: neuroendocrine tumors, metformin, clinical trial,
Introduction: We have shown immunohistochemistry (IHC) expression of estrogen (ER) and progesterone receptors (PR) in 20.8% and 18.8% of 96 NET patients (pts). An old clinical trial (Mortel C, 1984) suggested antitumor effects of estrogen/progesterone-directed therapies in NET. Yet the effects of an antiestrogen agent in NET pts whose tumor express ER and/or PR are unknown.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Riechelmann R
Authors: Riechelmann R, Donadio M, Felismino T, Fonseca de Jesus V, Mello C,
Keywords: neuroendocrine, estrogen, progesterone, clinical trial,
Introduction: Intolerance of Octreotide is about 10 % of cases
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author:
Authors: Gorbunova V, Orel N, Emelianova G, Kuzminov A, Markovich A,
Keywords: Octreotide, Lanreotide, intolerance, NETs,